Clinical trial
Safety, Tolerability and Effectiveness of Glocophage�SR in patients with type-2 Diabetes and Chronic Kidney Disease (eGFR 30 to 45mL/minute/1.73m2)
1% Change in HbA1c at the end of study from baseline in the Glucophage� SR group of the study, compared to placebo.
| Category | Value |
|---|---|
| Study start date | 2012-08-20 |